Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product Application End User

Description

List of Tables

Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, PRP, CAR T Cell, Tissue Engineering) Application (Oncology, Cardiovascular, Neurology, Immunology) End User (Hospital, ASC) - Global Forecast to 2031

The regenerative medicine market is projected to reach $78.53 billion by 2031, at a CAGR of 20% from 2024 to 2031.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by increasing approvals of regenerative medicine, advances in regenerative medicine, rising incidences of target diseases, increasing funding for the development of regenerative medicine, and increasing applications of regenerative medicine in newer therapy areas.

Furthermore, the rising demand for personalized medicine, rising demand for organ transplants, and increasing number of products in the pipeline provide a significant growth opportunity for this market. However, the high cost of treatment and ethical issues associated with stem cells may restrain the growth of this market. Additionally, unfavorable reimbursement policies and manufacturing challenges pose a major challenge for the players operating in this market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the global regenerative medicine market are Novartis AG (Switzerland), Biogen Inc. (U.S.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche AG (Switzerland), Integra Life Sciences (U.S.), Sarepta Therapeutics, Inc. (U.S.), Bayer AG (Germany), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (U.K.), GSK plc (U.K.), Takeda Pharmaceutical Company Limited (Japan), Astellas Pharma (Japan), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol Myers Squibb (U.S.), Cook Group Incorporated (U.S.), Pfizer Inc. (U.S.), Merck KGaA (Germany), and Vericel Corporation (U.S.).

Among products, in 2024, the cell therapy segment is expected to account for the largest share of 50.6% of the regenerative medicine market. This segment's large market share can be attributed to the extensive utilization of cell therapies in treating various conditions such as cancer, autoimmune diseases, cardiovascular ailments, and other chronic illnesses. The rising prevalence of chronic diseases has led to a surge in the adoption of cell therapies, supporting the largest share.

Among applications, in 2024, the oncology segment is expected to account for the largest share of the regenerative medicine market. Regenerative medicine offers various approaches, such as stem cell therapy, gene therapy, and tissue engineering, for treating cancer. This segment's large market share can be attributed to the increasing prevalence of cancer, the growing demand for personalized therapies, and recent approvals for cancer therapy.

Among end users, in 2024, the hospitals & clinics segment is expected to account for the larger share of the regenerative medicine market. This segment's large market share can be attributed to the rising number of patient visits to hospitals, the growing number of hospitals, and the availability of advanced technological resources and funding for these healthcare facilities. Funding is often provided to hospitals & clinics to establish dedicated regenerative medicine facilities.

An in-depth analysis of the geographical scenario of the global regenerative medicine market provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region.

In 2024, North America is expected to account for the largest share of the 53.3% of regenerative medicine market. North America's significant market share can be attributed to the increasing prevalence of target diseases such as cancer and cardiovascular diseases, growing funding for the development of regenerative medicine, the presence of key market players in the region, and the rising number of clinical trials.

Scope of the Report:

Regenerative Medicine Market Assessment-by Product

Gene Therapy
Cell Therapy
- Stem Cell Therapy
Autologous Therapy
Allogenic Therapy
- Platelet Rich Plasma Therapy
- Cell-based Immunotherapy
CAR T Cell Therapy
Other Cell-based Immunotherapies
Tissue-Engineering

Note: Other cell-based immunotherapies include NK Cell Therapy and Dendritic Cell Therapy

Regenerative Medicine Market Assessment-by Application

Cardiovascular Diseases
Ophthalmology Diseases
Oncology
Neurological Diseases
Immunology & Inflammation
Musculoskeletal Diseases
Dermatological Diseases
Other Applications

Note: Other applications include wound care, orthopedics, and sports injuries.

Regenerative Medicine Market Assessment-by End User

Hospitals & Clinics
Ambulatory Surgical Centers

Regenerative Medicine Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K
- Italy
- Spain
- Switzerland
- Denmark
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Product Code: MRHC - 1041181

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection and Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. Increasing Approvals of Regenerative Medicine
- 4.2.2. Advances in Regenerative Medicine
- 4.2.3. Rising Incidences of Target Diseases
- 4.2.4. Increasing Funding for the Development of Regenerative Medicine
- 4.2.5. Increasing Applications of Regenerative Medicine in Newer Therapy Areas
4.3. Restraints
- 4.3.1. High Cost of Treatment
- 4.3.2. Ethical Issues Associated with Stem Cells
4.4. Opportunities
- 4.4.1. Rising Demand for Personalized Medicine
- 4.4.2 Rising Demand for Organ Transplants
- 4.4.3. Increasing Number of Products in the Pipeline
4.5. Challenges
- 4.5.1. Unfavorable Reimbursement Policies
- 4.5.2. Manufacturing Challenges
4.6. Factor Analysis
4.7. Trends
4.8. Regulatory Analysis
4.9. Porter's Five Force Analysis
4.10. Investment & Funding Scenario
4.11. Pipeline Analysis

5. Regenerative Medicine Market Assessment-by Product

5.1. Overview
5.2. Gene Therapy
5.3. Cell Therapy
- 5.3.1. Stem Cell Therapy
  - 5.3.1.1. Autologous Therapy
  - 5.3.1.2. Allogenic Therapy
- 5.3.2. Platelet Rich Plasma Therapy
- 5.3.3. Cell-based Immunotherapy
  - 5.3.3.1. CAR T Cell Therapy
  - 5.3.3.2. Other Cell-based Immunotherapies
5.5. Tissue Engineering

6. Regenerative Medicine Market Assessment-by Application

6.1. Overview
6.2. Cardiovascular Diseases
6.3. Ophthalmic Diseases
6.4. Oncology
6.5. Neurological Diseases
6.6. Immunology & Inflammation
6.7. Musculoskeletal Diseases
6.8. Dermatological Diseases
6.9. Other Applications

7. Regenerative Medicine Market Assessment-by End User

7.1. Overview
7.2. Hospital & Clinics
7.3. Ambulatory Surgical Centers

8. Regenerative Medicine Market Assessment-by Geography

8.1. Overview
8.2. North America
- 8.2.1. U.S.
- 8.2.2. Canada
8.3. Europe
- 8.3.1. Germany
- 8.3.2. France
- 8.3.3. U.K.
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Switzerland
- 8.3.7. Netherlands
- 8.3.8. Sweden
- 8.3.8. Rest of Europe (RoE)
8.4. Asia-Pacific
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. South Korea
- 8.4.5. Australia
- 8.4.6. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
- 8.5.1. Brazil
- 8.5.2. Mexico
- 8.5.3. Rest of Latin America (RoLATAM)
8.6. Middle East & Africa

9. Competition Analysis

9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
- 9.4.1. Industry Leaders
- 9.4.2. Market Differentiators
- 9.4.3. Vanguards
- 9.4.4. Emerging Companies
9.5. Market Ranking, by Key Players (2023)

10. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)

10.1. Novartis AG
10.2. Biogen Inc.
10.3. AstraZeneca plc
10.4. F. Hoffmann-La Roche AG
10.5. Integra Life Sciences
10.6. Sarepta Therapeutics, Inc.
10.7. Bayer AG
10.8. Amgen Inc.
10.9. CORESTEMCHEMON Inc.
10.10. Smith & Nephew plc
10.11. GSK plc
10.12. Takeda Pharmaceutical Company Limited
10.13. Astellas Pharma
10.14. Medtronic plc
10.15. AbbVie Inc.
10.16. Bristol Myers Squibb
10.17. Cook Group Incorporated
10.18. Pfizer Inc.
10.19. Merck KGaA
10.20. Vericel Corporation

(Note: SWOT Analysis Will be Provided for the Top 5 Companies.)

11. Appendix

11.1. Available Customization
11.2. Related Reports